Orencia — Total Revenues
Bristol-Myers Squibb Orencia — Total Revenues decreased by 18.8% to $818M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.2%, from $770M to $818M. Over 4 years (FY 2021 to FY 2025), Orencia — Total Revenues shows an upward trend with a 2.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful patient retention, while a decrease may signal increased competition from biosimilars or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total global net sales generated from the Orencia product line, a biologic therapy primarily...
Peer comparison
Similar to other major biologic drug revenue streams in the pharmaceutical industry, performance is typically compared against peer immunology franchises and market penetration rates for autoimmune therapies.
bmy_segment_orencia_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $814M | $870M | $864M | $792M | $876M | $883M | $913M | $764M | $927M | $925M | $985M | $798M | $948M | $936M | $1B | $770M | $963M | $964M | $1.01B | $818M |
| QoQ Change | — | +6.9% | -0.7% | -8.3% | +10.6% | +0.8% | +3.4% | -16.3% | +21.3% | -0.2% | +6.5% | -19.0% | +18.8% | -1.3% | +6.8% | -23.0% | +25.1% | +0.1% | +4.6% | -18.8% |
| YoY Change | — | — | — | — | +7.6% | +1.5% | +5.7% | -3.5% | +5.8% | +4.8% | +7.9% | +4.5% | +2.3% | +1.2% | +1.5% | -3.5% | +1.6% | +3.0% | +0.8% | +6.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's orencia — total revenues?
- Bristol-Myers Squibb (BMY) reported orencia — total revenues of $818M in Q1 2026.
- How has Bristol-Myers Squibb's orencia — total revenues changed year-over-year?
- Bristol-Myers Squibb's orencia — total revenues increased by 6.2% year-over-year, from $770M to $818M.
- What is the long-term trend for Bristol-Myers Squibb's orencia — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's orencia — total revenues has grown at a 2.9% compound annual growth rate (CAGR), from $3.31B to $3.71B.
- What does orencia — total revenues mean?
- Total global sales generated by the Orencia drug product line.